Breast Cancer > Boston, MA, USA
(50 of 497)
Sort:
NCT03678883
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Recruiting • Phase II • Stages III, IV • Post-Menopausal • Interventional
Rhode Island Hospital
Site Contact
Benedito Carneiro, MD
Benedito.Carneiro@Lifespan.org
Last Updated:
05/25/2021
41.85 miles away from Boston, MA, USA
NCT03130439
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.
Terminated • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Sara Tolaney, MD, MPH
Last Updated:
11/18/2021
2.91 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Principal Investigator
Sara Tolaney, MD, MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT05169567
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Recruiting • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional
Massachusetts General Hospital
Site Contact
617-726-2943
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Last Updated:
12/28/2021
0.55 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Site Contact
603-913-3673
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Last Updated:
12/28/2021
2.95 miles away from Boston, MA, USA
Vernon Cancer Center Pharmacy, Massachusetts General Cancer Center at Newton-Wellesley
Site Contact
617-219-1230
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Last Updated:
12/28/2021
9.79 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Site Contact
603-913-3673
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Last Updated:
10/21/2022
13.71 miles away from Boston, MA, USA
Massachusetts General Hospital
Site Contact
617-726-2943
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Last Updated:
12/28/2021
14.51 miles away from Boston, MA, USA
NCT02823262
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.
Completed • Phase NA • Stages 0, I, II, III • ER positive • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional
Beth Israel Deaconess Medical Center
Principal Investigator
Mara Schonberg, MD MPH
Last Updated:
05/25/2021
2.73 miles away from Boston, MA, USA
Beth Israel Deaconess Medical Center
Principal Investigator
Mara Schonberg, MD MPH
Last Updated:
11/18/2021
2.75 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Principal Investigator
Mara Schonberg, MD MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Principal Investigator
Mara Schonberg, MD MPH
Last Updated:
11/18/2021
2.96 miles away from Boston, MA, USA
NCT00887536
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.
Completed • Phase III • Stages I, II, III • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional
Saint Anne's Hospital
Principal Investigator
Norman Wolmark, MD
Last Updated:
05/25/2021
46.42 miles away from Boston, MA, USA
Hartford Hospital
Principal Investigator
Norman Wolmark, MD
Last Updated:
05/25/2021
93.12 miles away from Boston, MA, USA
University of Connecticut
Principal Investigator
Norman Wolmark, MD
Last Updated:
05/25/2021
98.93 miles away from Boston, MA, USA
University of Connecticut
Principal Investigator
Norman Wolmark, MD
Last Updated:
11/18/2021
98.98 miles away from Boston, MA, USA
NCT04711252
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.
Recruiting • Phase III • Stage IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional
Research Site
Site Contact
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Last Updated:
10/04/2022
0.42 miles away from Boston, MA, USA
NCT03783546
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to reduce hot flashes.
Active, not recruiting • Phase NA • Stages I, II, III • ER positive • PR positive • Post-Menopausal • Brain Metastases absent • Interventional
Dana Farber Cancer Institute
Principal Investigator
Weidong Lu, PhD, MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT04379570
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting • Phase III • Stages I, II, III • ER positive • PR positive • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional
Dana-Farber Cancer Institute
Site Contact
Site Public Contact
877-442-3324
Principal Investigator
Katherine E. Reeder-Hayes, MD
Last Updated:
12/16/2021
2.95 miles away from Boston, MA, USA
Winchester Hospital
Site Contact
Site Public Contact
ctsucontact@westat.com
888-823-5923
Principal Investigator
Katherine E. Reeder-Hayes, MD
Last Updated:
05/25/2021
8.01 miles away from Boston, MA, USA
Lahey Hospital and Medical Center
Site Contact
Site Public Contact
cancerclinicaltrials@lahey.org
781-744-3421
Principal Investigator
Katherine E. Reeder-Hayes, MD
Last Updated:
05/25/2021
11.33 miles away from Boston, MA, USA
Lahey Medical Center-Peabody
Site Contact
Katherine E. Reeder-Hayes, MD
kreeder@med.unc.edu
919-445-6147
Principal Investigator
Katherine E. Reeder-Hayes, MD
Last Updated:
05/25/2021
13.52 miles away from Boston, MA, USA
Beverly Hospital
Site Contact
Site Public Contact
978-922-3000
Principal Investigator
Katherine E. Reeder-Hayes, MD
Last Updated:
05/25/2021
16.94 miles away from Boston, MA, USA
NCT02826434
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study is studying the safety, tolerability, and immune response of these treatments. The names of the study interventions involved in this study are: PVX-410 Vaccine Durvalumab (MEDI4736)
Active, not recruiting • Phase I • Stages I, II • ER negative • PR negative • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional
Massachusetts general Hospital
Principal Investigator
Steven Isakoff, MD, PhD
Last Updated:
02/25/2022
0.55 miles away from Boston, MA, USA
Beth Israel Deaconess Medical Center
Principal Investigator
Steven Isakoff, MD, PhD
Last Updated:
05/25/2021
2.73 miles away from Boston, MA, USA
Beth Israel Deaconess Medical Center
Principal Investigator
Steven Isakoff, MD, PhD
Last Updated:
11/18/2021
2.75 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Principal Investigator
Steven Isakoff, MD, PhD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Principal Investigator
Steven Isakoff, MD, PhD
Last Updated:
11/18/2021
2.96 miles away from Boston, MA, USA
NCT03078751
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer
Completed • Phase II • Stages I, II, III • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional
Mass General Hospital SC
Principal Investigator
Novartis Pharmaceuticals
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Kent County Hosptial
Principal Investigator
Novartis Pharmaceuticals
Last Updated:
05/25/2021
50.08 miles away from Boston, MA, USA
Eastern Connecticut Hematology and Oncology Associates
Principal Investigator
Novartis Pharmaceuticals
Last Updated:
05/25/2021
77.36 miles away from Boston, MA, USA
Eastern Connecticut Hematology & Oncology Associates
Principal Investigator
Novartis Pharmaceuticals
Last Updated:
05/25/2021
77.36 miles away from Boston, MA, USA
Baystate Medical Associates
Principal Investigator
Novartis Pharmaceuticals
Last Updated:
05/25/2021
80.72 miles away from Boston, MA, USA
NCT02983045
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3.
Completed • Phases I, II • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases present • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Study Director
Last Updated:
12/02/2021
2.91 miles away from Boston, MA, USA
NCT02637531
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
Active, not recruiting • Phase I • Stages III, IV • ER negative • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional
Massachusetts General Hospital
Principal Investigator
Feng Chi, MD
Last Updated:
11/18/2021
0.48 miles away from Boston, MA, USA
Massachusetts General Hospital
Principal Investigator
Feng Chi, MD
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Beth Israel Deaconess Medical Center
Principal Investigator
Feng Chi, MD
Last Updated:
05/25/2021
2.73 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Principal Investigator
Feng Chi, MD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT03858322
'ADVANCE' (A Pilot Trial)
This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Active, not recruiting • Phase I • Stages I, II, III • ER negative • Post-Menopausal • Brain Metastases absent • Interventional
Dana Farber Cancer Institute
Principal Investigator
Rachel Freedman, MD, MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
Brigham and Women's Hospital
Principal Investigator
Rachel Freedman, MD, MPH
Last Updated:
05/25/2021
2.96 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Principal Investigator
Rachel Freedman, MD, MPH
Last Updated:
11/18/2021
2.96 miles away from Boston, MA, USA
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital
Principal Investigator
Rachel Freedman, MD, MPH
Last Updated:
05/25/2021
13.71 miles away from Boston, MA, USA
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center
Principal Investigator
Rachel Freedman, MD, MPH
Last Updated:
05/25/2021
28.75 miles away from Boston, MA, USA
NCT03063619
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Active, not recruiting • Phase II • Stages 0, I, II, III, IV • Post-Menopausal • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Banu Arun, MD
Last Updated:
12/06/2021
2.95 miles away from Boston, MA, USA
NCT03471663
A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate preliminary anti-tumor activities in women with advanced or metastatic ER-positive, HER2-negative breast cancer.
Active, not recruiting • Phase I • Stages III, IV • ER positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional
NCT04278144
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
Recruiting • Phases I, II • Stages III, IV • HER2 positive • Post-Menopausal • Interventional
Dana-Farber Cancer Institute
Site Contact
DFCI Clinical Trials Hotline
877-338-7425
Principal Investigator
Bolt Clinical Development
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT03959891
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
This research is looking to find out if the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant can be an effective treatment for breast cancer.
Active, not recruiting • Phase I • Stages III, IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional
Massachusetts General Hospital Cancer Center
Principal Investigator
Aditya Bardia, MD
Last Updated:
11/18/2021
0.55 miles away from Boston, MA, USA
Massachusetts General Hospital Cancer Center
Principal Investigator
Aditya Bardia, MD
Last Updated:
11/18/2021
0.55 miles away from Boston, MA, USA
Massachusetts General Hospital Cancer Center
Principal Investigator
Aditya Bardia, MD
Last Updated:
05/03/2022
0.56 miles away from Boston, MA, USA
NCT05423730
Alcohol and Breast Cancer (ABC) Trial
This research study is a pilot study, which is the first time investigators are examining the effect of light alcohol consumption on sex hormones among postmenopausal women with estrogen receptor-positive (ER+) breast cancer taking an aromatase inhibitor The names of the study exposures involved in this study are: White wine White grape juice
Recruiting • Phase NA • Stages 0, I, II, III, IV • ER positive • Surgical • Post-Menopausal • Interventional
Beth Israel Deaconess Medical Center
Site Contact
Kenneth Mukamal, MD, MPH
kmukamal@bidmc.harvard.edu
617-754-1409
Principal Investigator
Kenneth Mukamal, MD, MPH
Last Updated:
06/22/2022
2.73 miles away from Boston, MA, USA
NCT02860000
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.
Active, not recruiting • Phase II • Stages III, IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Tufia Haddad
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT04478266
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: To compare the overall survival in both treatment arms To evaluate the objective response rate in both treatment arms To evaluate the duration of response in both treatment arms To evaluate the clinical benefit rate in both treatment arms To evaluate progression-free survival on next line of therapy To evaluate the pharmacokinetics of amcenestrant, and palbociclib To evaluate health-related quality of life in both treatment arms To evaluate the time to first chemotherapy in both treatment arms To evaluate safety in both treatment arms
Active, not recruiting • Phase III • Stages III, IV • ER positive • HER2 negative • CDK4/6 inhibitor absent • Medical Oncology • Post-Menopausal • Interventional
Investigational Site Number 8400002
Principal Investigator
Clinical Sciences & Operations
Last Updated:
05/25/2021
0.46 miles away from Boston, MA, USA
Investigational Site Number :8400017
Principal Investigator
Clinical Sciences & Operations
Last Updated:
05/03/2022
0.46 miles away from Boston, MA, USA
Investigational Site Number 8400015
Principal Investigator
Clinical Sciences & Operations
Last Updated:
05/25/2021
2.11 miles away from Boston, MA, USA
Investigational Site Number :8400015
Principal Investigator
Clinical Sciences & Operations
Last Updated:
10/02/2021
2.11 miles away from Boston, MA, USA
Investigational Site Number :8400077
Principal Investigator
Clinical Sciences & Operations
Last Updated:
10/02/2021
7.84 miles away from Boston, MA, USA
NCT02657343
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment. This research study is a way of gaining new knowledge about the combination of Ribociclib with other drugs as a possible treatment for this diagnosis.
Completed • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional
Massacusetts General Hospital
Principal Investigator
Sara Tolaney, MD MPH
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Principal Investigator
Sara Tolaney, MD MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT02939274
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metastases of breast cancer for which no curative or significantly palliative therapy exists, including chest wall therapy.
Unknown status • Phase II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional
Massachusetts General Hospital
Site Contact
Steven J Isakoff, MD PhD
617-726-4920
Principal Investigator
Steven J Isakoff, MD PhD
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Site Contact
Beth Overmoyer, MD
617-632-3800
Principal Investigator
Steven J Isakoff, MD PhD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT03058289
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also plans to test INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Completed • Phases I, II • Stages III, IV • Post-Menopausal • Brain Metastases present • Interventional
UMASS Memorial Medical Center
Principal Investigator
Ian B. Walters, M.D.
Last Updated:
05/25/2021
36.35 miles away from Boston, MA, USA
NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.
Recruiting • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional
Massachusetts General Hospital
Site Contact
Dejan Juric, MD
djuric@partners.org
617-724-4000
Principal Investigator
Judson Englert, MD
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Site Contact
877-338-7425
Principal Investigator
Judson Englert, MD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Site Contact
877-338-7425
Principal Investigator
Judson Englert, MD
Last Updated:
11/18/2021
2.96 miles away from Boston, MA, USA
NCT04072952
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Recruiting • Phases I, II • Stages III, IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional
Clinical Trial Site
Site Contact
Arvinas Estrogen Receptor, Inc.
clinicaltrialsARV-471@arvinas.com
475-345-3366
Last Updated:
02/12/2022
0.13 miles away from Boston, MA, USA
Massachusetts General Hospital
Site Contact
Arvinas Estrogen Receptor, Inc.
clinicaltrialsARV-471@arvinas.com
475-345-3366
Last Updated:
01/23/2023
0.55 miles away from Boston, MA, USA
Clinical Trial Site
Site Contact
Arvinas Estrogen Receptor, Inc.
clinicaltrialsARV-471@arvinas.com
475-345-3366
Last Updated:
02/12/2022
3.1 miles away from Boston, MA, USA
NCT04682431
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
Recruiting • Phase I • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional
Massachusetts General Hospital
Site Contact
Denise Deegan
ddeegan@pionyrtx.com
650-825-6140
Principal Investigator
Len Reyno, MD
Last Updated:
10/17/2022
0.55 miles away from Boston, MA, USA
NCT03601897
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
Active, not recruiting • Phases I, II • Stage IV • Medical Oncology • Post-Menopausal • Interventional
NCT04538742
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
Recruiting • Phases I, II • Stages III, IV • Post-Menopausal • Brain Metastases present • Interventional
Research Site
Site Contact
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Last Updated:
01/13/2022
41.46 miles away from Boston, MA, USA
NCT04244552
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
Recruiting • Phase I • Stages III, IV • PR negative • HER2 negative • Post-Menopausal • Interventional
Massachusetts General Hospital
Site Contact
Nick Higgins
nhiggins@atreca.com
650-453-5279
Principal Investigator
Sudha Khurana, PhD
Last Updated:
03/11/2022
0.55 miles away from Boston, MA, USA
NCT01975831
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment. The primary study objective was to determine the maximum tolerated dose (MTD) and safety profile of the durvalumab and tremelimumab combination. Secondary objectives were to evaluate the pharmacokinetics (PK) and immunogenicity of durvalumab and tremelimumab, and the antitumor activity (tumor response, progression-free survival [PFS], and overall survival [OS]) of the durvalumab and tremelimumab combination. (Note: Collection of PK and immunogenicity samples was removed by amendment; analysis was not done.) Exploratory objectives were to evaluate the biological activity of the durvalumab and tremelimumab combination.
Completed • Phase I • Stages III, IV • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Jedd D Wolchok, MD, PhD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT02498613
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.
Active, not recruiting • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Joseph W Kim
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT02623972
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Active, not recruiting • Phase II • Stages I, II, III • HER2 negative • Post-Menopausal • Interventional
Brigham and Women's Hospital
Principal Investigator
Filipa Lynce, MD
Last Updated:
11/18/2021
2.95 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Principal Investigator
Filipa Lynce, MD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
Brigham and Women's Hospital
Principal Investigator
Filipa Lynce, MD
Last Updated:
05/25/2021
2.96 miles away from Boston, MA, USA
NCT05104866
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.
Active, not recruiting • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases present • Interventional
NCT02163694
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2 (BRCA1; BRCA2) mutation in Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic or locally advanced unresectable breast cancer. The secondary objectives of the study are to assess overall survival (OS), clinical benefit rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS on subsequent therapy (PFS2) in participants treated with veliparib in combination with C/P versus placebo in combination with C/P.
Active, not recruiting • Phase III • Stages III, IV • HER2 negative • Somatic BRCA1/2 present • Post-Menopausal • Interventional
UMass Memorial Medical Center /ID# 129067
Principal Investigator
ABBVIE INC.
Last Updated:
06/16/2021
36.36 miles away from Boston, MA, USA
UMass Chan Medical School /ID# 129067
Principal Investigator
ABBVIE INC.
Last Updated:
01/25/2022
36.4 miles away from Boston, MA, USA
Baystate Medical Center /ID# 139461
Principal Investigator
ABBVIE INC.
Last Updated:
06/16/2021
80.72 miles away from Boston, MA, USA
NCT02734004
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
Active, not recruiting • Phases I, II • Stages III, IV • HER2 negative • Medical Oncology • Post-Menopausal • Interventional
Research Site
Principal Investigator
Susan Domchek, MD
Last Updated:
11/18/2021
0.42 miles away from Boston, MA, USA
NCT01905592
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice
Terminated • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Interventional
GSK Investigational Site
Principal Investigator
GSK Clinical Trials
Last Updated:
11/18/2021
0.6 miles away from Boston, MA, USA
GSK Investigational Site
Principal Investigator
GSK Clinical Trials
Last Updated:
05/25/2021
1.76 miles away from Boston, MA, USA
NCT02296801
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been treated. Letrozole is a type of endocrine therapy called an aromatase inhibitor (AI) and is standard treatment for post-menopausal women with ER-positive/HER2-negative breast cancer.
Completed • Phase II • Stages I, II • Medical Oncology • Post-Menopausal • Interventional
Women and Infants Hospital of Rhode Island
Principal Investigator
Norman Wolmark, MD
Last Updated:
05/25/2021
42.05 miles away from Boston, MA, USA
NCT03584009
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, locally advanced or Metastatic Breast Cancer (MBC) who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks. As of 9th October 2020, participants in the Venetoclax + Fulvestrant arm, have all discontinued Venetoclax treatment and have continued on Fulvestrant treatment alone.
Terminated • Phase II • Stages III, IV • ER positive • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Interventional
Massachusetts General Hospital.
Principal Investigator
Clinical Trials
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Mass General/North Shore Cancer
Principal Investigator
Clinical Trials
Last Updated:
11/18/2021
14.51 miles away from Boston, MA, USA
Mass General/North Shore Cancer
Principal Investigator
Clinical Trials
Last Updated:
05/25/2021
14.51 miles away from Boston, MA, USA
NCT03316586
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: Cabozantinib (XL184) Nivolumab
Completed • Phase II • Stage IV • ER negative • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional
Dana-Farber Cancer Institute
Principal Investigator
Sara Tolaney, MD, MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT02338349
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer.
Completed • Phase I • Stages III, IV • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional
Radius Pharmaceuticals, Inc.
Principal Investigator
Sr. Director, Clinical Operations
Last Updated:
05/25/2021
11.37 miles away from Boston, MA, USA
NCT03945721
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
Recruiting • Phase I • Stages I, II, III • ER negative • PR negative • HER2 negative • Radiation • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional
Massachusetts General Hospital Cancer Center
Site Contact
Alice Ho, MD
alice.ho@mgh.harvard.edu
617-724-1160
Principal Investigator
Alice Ho, MD
Last Updated:
05/03/2022
0.56 miles away from Boston, MA, USA
Dana Farber Cancer Institute/Brigham and Women's Hospital
Site Contact
Jennifer Bellon, MD
jbellon@lroc.harvard.edu
Principal Investigator
Alice Ho, MD
Last Updated:
05/25/2021
2.93 miles away from Boston, MA, USA
NCT03573661
A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers
The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.
Completed • Phase O • Stages 0, I, II, III • Post-Menopausal • Brain Metastases absent • Interventional
Lahey Hospital & Medical Center (Lahey Clinic)
Principal Investigator
Richard J Barth, Jr., MD
Last Updated:
05/25/2021
11.34 miles away from Boston, MA, USA
St. Joseph Hospital
Principal Investigator
Richard J Barth, Jr., MD
Last Updated:
11/18/2021
34.37 miles away from Boston, MA, USA
Cheshire Medical Center
Principal Investigator
Richard J Barth, Jr., MD
Last Updated:
05/25/2021
74.67 miles away from Boston, MA, USA
NCT02129686
A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
This study is being done to evaluate the potential benefits of using acupuncture to reduce symptoms of tingling, burning, numbness and pain in the hands and feet of women with peripheral neuropathy after completion of chemotherapy for breast cancer.
Completed • Phase NA • Stages I, II, III • ER negative • Surgical • Post-Menopausal • Interventional
Dana Farber Cancer Institute
Principal Investigator
Weidong Lu, M.B., MPH, Ph.D
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
Dana Farber Cancer Institute
Principal Investigator
Weidong Lu, M.B., MPH, Ph.D
Last Updated:
11/18/2021
2.96 miles away from Boston, MA, USA
NCT03822312
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy
This research study is evaluating whether the use of digital breast tomosynthesis and near-infrared tomographic optical breast imaging (DBT-TOBI) scans can predict the response of triple negative or HER2+ breast cancer to neoadjuvant chemotherapy. The study radiologic scan involved in this study is digital breast tomosynthesis (also called 3 Dimensional mammogram) combined with near-infrared tomographic optical breast imaging, or DBT-TOBI.
Active, not recruiting • Phase NA • Stages I, II, III • Post-Menopausal • Brain Metastases absent • Interventional
Massachusetts General Hospital Cancer Center
Principal Investigator
Steven J Isakoff, MD
Last Updated:
11/18/2021
0.55 miles away from Boston, MA, USA
Massachusetts General Hospital Cancer Center
Principal Investigator
Steven J Isakoff, MD
Last Updated:
05/25/2021
0.56 miles away from Boston, MA, USA
NCT03051659
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.
Active, not recruiting • Phase II • Stage IV • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional
Massachusetts General Hospital
Principal Investigator
Sara Tolaney, MD MPH
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Beth Israel Deaconess Medical Center
Principal Investigator
Sara Tolaney, MD MPH
Last Updated:
05/25/2021
2.73 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Principal Investigator
Sara Tolaney, MD MPH
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT01921335
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
The purpose of this study is to test the safety of different doses of ARRY-380 in combination with trastuzumab. Trastuzumab is an FDA approved drug for the treatment of HER2 metastatic breast cancer. However, the combination of ARRY-380 and trastuzumab has not yet been tested. Both agents block the HER2 receptor, which is thought to be overactive in HER2-positive breast cancer. It is thought that ARRY-380 and trastuzumab might work together because they attach to different parts of the HER2 receptor and prevent it from functioning. Because HER2 positive breast cancer contains high levels of HER2 receptor, but normal cells in your body generally do not, the drugs may be able to "target" the cancer cells. In addition, in laboratory studies, ARRY-380 appears to have some penetration into the brain.
Active, not recruiting • Phase I • Stage IV • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional
Massachusetts General Hospital
Principal Investigator
Nancy Lin, MD
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Dana-Farber Cancer Institute
Principal Investigator
Nancy Lin, MD
Last Updated:
05/25/2021
2.95 miles away from Boston, MA, USA
NCT04829604
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Active, not recruiting • Phase II • Stage IV • Post-Menopausal • Brain Metastases present • Interventional
Research Site
Principal Investigator
Ambrx
Last Updated:
07/26/2022
2.35 miles away from Boston, MA, USA
NCT05091528
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2). Participants will be enrolled into each Arm based on cancer diagnosis and prior therapies.
Terminated • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional
Massachusetts General Hospital
Principal Investigator
Naomi Hunder, MD
Last Updated:
01/20/2022
0.55 miles away from Boston, MA, USA
NCT05234606
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4 expression.
Recruiting • Phases I, II • Stages III, IV • HER2 negative • Medical Oncology • Post-Menopausal • Interventional
Massachusetts General Hospital
Site Contact
Clinical Trials Operations
ClinOps@Silverbacktx.com
206 456-2900
Principal Investigator
Natasha Angra, PharmD
Last Updated:
02/11/2022
0.55 miles away from Boston, MA, USA
NCT00781612
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Recruiting • Phase II • Stage IV • HER2 positive • Medical Oncology • Post-Menopausal • Interventional
Massachusetts General Hospital
Site Contact
Reference Study ID Number: BO25430 www.roche.com/about_roche/roche_worldwide.htm
global-roche-genentech-trials@gene.com
Last Updated:
05/25/2021
0.55 miles away from Boston, MA, USA
Dana Farber Cancer Institute; Breast Oncology
Site Contact
Reference Study ID Number: BO25430 www.roche.com/about_roche/roche_worldwide.htm
global-roche-genentech-trials@gene.com
Last Updated:
05/25/2021
2.96 miles away from Boston, MA, USA
New England Cancer Specialists
Site Contact
Reference Study ID Number: BO25430 www.roche.com/about_roche/roche_worldwide.htm
global-roche-genentech-trials@gene.com
Last Updated:
05/25/2021
93.53 miles away from Boston, MA, USA
© 2023 Outcomes4Me Inc. All rights reserved.